# PRODUCT SPECIFICATION



## HAH 002–01B Anti human Butyrylcholinesterase, biotynylated

mouse monoclonal antibody

Article No.	96973		
Product Name	HAH 002-01B Anti Human Butyrylcholinesterase, biotinylated		
Clone	3E8		
Subclass	lgG1 / kappa		
Description	Concentration:	Protein-A purified 1 mg/mL ± 10%, based on A details. PBS, pH 7.2 – 7.4 -18 °C or colder	. <sub>280</sub> . See Certificate of Analysis for
Antigen	Butyrylcholinesterase (BChE, EC 3.1.1.8.) is a tetrameric glycoprotein with a molecular mass of 350 kDa, which consists of four subunits, each with a molecular mass of app. 90 kDa. BChE is synthetized in the liver, and is predominantly found in serum, liver and pancreas. BChE is the principal cocaine-metabolizing enzyme in human serum and serves as scavenger for toxic organophosphorus pesticides and nerve agents (1,2)		
Immunogen	Butyrylcholinesterase purified from human plasma.		
Specificity	HAH 002-01 reacts with BChE from human serum and plasma.		
EPITOPE SPECIFICITY	Not determined.		
Reactivity	HAH 002-01 reacts with BChE from human serum in crossed immunoelectrophoresis and in sandwich ELISA using HAH 002-01 as capture antibody and biotinylated HAH 002-01 as detection antibody, respectively (3,4). Serum cholinesterase activity can be measured by enzyme antigen immunoassay (EAIA) using HAH 002-01 as catching antibody (5). HAH 002-01 can be used for purification of serum BChE by immunoaffinity chromatography (3) and for immunomagnetic separation of human BChE (6-8). HAH 002-01 has been used in a in a quantitative method that combines immunomagnetic separation of human BChE and liquid chromatograph tandem mass spectrometry for quantitative detection of organophosphate nerve agent expure (6-8).		
Culture Medium	Dulbecco's modified Eagle's medium with 10% fetal calf serum.		
Fusion Partner	X63-Ag8.653.		
Immunization	Female CF1xBalb/c F1 hybrid mice were immunized i.p. with immunogen adsorbed onto Al(OH) <sub>3</sub> .		
Application	Method EAIA ELISA Immunoaffinity Chromatography Immunoblotting Immunofluorescence	Usability Yes Yes Yes No N.D	References           1,5           3,4           3

@ ssi-antibodies@ssi.dk
w ssi.dk

## www.ssi.dk/antibodies

See next page

Version 4 • November 2022

### HAH 002-01 Anti human Butyrylcholinesterase

mouse monoclonal antibody



#### References

1) Yang W, Pan Y, Zheng F, Cho H, Tai HH, Zhan CG. Free-Energy Perturbation Simulation on Transition States and Redesign of Butyrylcholinesterase Biophys J. 2009 Mar 4; 96(5): 1931–1938.

.....

2) Masson P, Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons; catalytic complexities and hysteretic behavior. Arch Biochem Biophys. 2010:15:494(2): 107.

3) Brock A, Mortensen V, Rasmussen Loft AG, Nørgaard-Pedersen B. Enzyme Immunoassay of Human Cholinesterase (EC 3.1.1.8) Comparison of immunoreactive substance concentration with catalytic activity concentration in randomly selected serum samples from healthy individuals. J Clin Chem Biochem. 1990:28(4):221-4.

4) Aoki Y, Helzlsouer KJ, Strickland PT. Arylesterase phenotype-specific positive association between arylesterase activity and cholinesterase specific activity in human serum. Int J Environ Res Public Health. 2014:11(2):1422-43.

5) Hangaard J1, Whittaker M, Loft AG, Nørgaard-Pedersen B. Quantification and phenotyping of serum cholinesterase by enzyme antigen immunoassay: methodological aspects and clinical applicability. Scand J Clin Lab Invest. 1991:51(4):349-58.

6) Sporty JL1, Lemire SW, Jakubowski EM, Renner JA, Evans RA, Williams RF, Schmidt JG, van der Schans MJ, Noort D, Johnson RC. Immunomagnetic separation and quantification of butyrylcholinesterase nerve agent adducts in human serum. Anal Chem. 2010:82(15):6593-600.

#### Conditions

For research use only. Not for use in diagnostic procedures. Not for therapeutic use or applications.

The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall Statens Serum Institut be responsible for loss of profits or indirect consequential losses resulting from use of its products. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.